COVID vaccine recommendations in dermatologic patients on immunosuppressive agents : Lessons learned from pandemic
© 2022 Wiley Periodicals LLC..
BACKGROUND: Since SARS-CoV2 vaccines were approved without enough long-term monitoring due to emergent situations, some issues have been raised about timing and protocol of receiving them by patients treated by different immunosuppressive agents.
AIM AND METHOD: Here, we present different aspects of SARS-CoV-2 vaccination in such patients in the field of dermatology.
RESULT: In brief, SARS-CoV-2 vaccination is recommended in all dermatologic patients, regardless of their disorders and therapeutic regimens. Nevertheless, special considerations should be given to the immunosuppressive therapy and its association with vaccination timing due to the decreased immunogenicity of vaccines in this setting.
CONCLUSION: Novel biologic immunotherapies are advantageous over conventional systemic therapies not only in their safety and selective functions but also in this aspect that many of them do not affect vaccines immunogenicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Journal of cosmetic dermatology - 21(2022), 12 vom: 07. Dez., Seite 6568-6573 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aryanian, Zeinab [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biologic therapies |
|---|
| Anmerkungen: |
Date Completed 05.01.2023 Date Revised 26.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jocd.15448 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347298702 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347298702 | ||
| 003 | DE-627 | ||
| 005 | 20231226033512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jocd.15448 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347298702 | ||
| 035 | |a (NLM)36214611 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aryanian, Zeinab |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID vaccine recommendations in dermatologic patients on immunosuppressive agents |b Lessons learned from pandemic |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2023 | ||
| 500 | |a Date Revised 26.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Since SARS-CoV2 vaccines were approved without enough long-term monitoring due to emergent situations, some issues have been raised about timing and protocol of receiving them by patients treated by different immunosuppressive agents | ||
| 520 | |a AIM AND METHOD: Here, we present different aspects of SARS-CoV-2 vaccination in such patients in the field of dermatology | ||
| 520 | |a RESULT: In brief, SARS-CoV-2 vaccination is recommended in all dermatologic patients, regardless of their disorders and therapeutic regimens. Nevertheless, special considerations should be given to the immunosuppressive therapy and its association with vaccination timing due to the decreased immunogenicity of vaccines in this setting | ||
| 520 | |a CONCLUSION: Novel biologic immunotherapies are advantageous over conventional systemic therapies not only in their safety and selective functions but also in this aspect that many of them do not affect vaccines immunogenicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a biologic therapies | |
| 650 | 4 | |a dermatologic conditions | |
| 650 | 4 | |a immunosuppressive therapies | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Balighi, Kamran |e verfasserin |4 aut | |
| 700 | 1 | |a Afshar, Zeinab Mohseni |e verfasserin |4 aut | |
| 700 | 1 | |a Zamanian, Mohammad Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Razavi, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Hatami, Parvaneh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cosmetic dermatology |d 2002 |g 21(2022), 12 vom: 07. Dez., Seite 6568-6573 |w (DE-627)NLM166816639 |x 1473-2165 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2022 |g number:12 |g day:07 |g month:12 |g pages:6568-6573 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jocd.15448 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2022 |e 12 |b 07 |c 12 |h 6568-6573 | ||